EP Patent

EP3735244B1 — Intranasal delivery of dihydroergotamine by precision olfactory device

Assigned to Impel Pharmaceuticals Inc · Expires 2022-11-23 · 3y expired

What this patent protects

Patent listed against dihydroergotamine-mesylate.

Drugs covered by this patent

dihydroergotamine-mesylate (DIHYDROERGOTAMINE MESYLATE)

Patent Metadata

Patent number: EP3735244B1
Jurisdiction: EP
Classification: —
Expires: 2022-11-23
Drug substance claim: No
Drug product claim: No
Assignee: Impel Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.